Four things to know:
1. Amwell priced 41.2 million shares of its Class A common stock at $18 per share. The total proceeds of the IPO are expected to hit $742 million before deducting underwriting discounts and commissions and offering expenses.
2. The price is up from the $14 to $16 per share expectations in Amwell’s statement to the U.S. Securities and Exchange Commission filed Sept. 8, which would have priced the IPO between $490 million and $560 million.
3. The public offering is expected to close Sept. 21, and the underwriters have a 30-day option to purchase around 6 million additional shares of Class A common stock at the initial IPO price, less underwriting discounts and commissions.
4. Morgan Stanley, Goldman Sachs & Co. and Piper Sandler are the lead joint book-running managers for the offering.
5. Amwell announced its IPO Aug. 24 in conjunction with a Google Cloud partnership. Google invested $100 million in the company to help scale telehealth for providers, insurers and patients.
More articles on telehealth:
Top 10 physician specialties using telemedicine
A timeline of telehealth support from the federal government during the pandemic
5 ways to fuse telehealth into primary care beyond the pandemic
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
